Journal: Cancer Medicine

Article Title: BRD9 is an essential regulator of glycolysis that creates an epigenetic vulnerability in colon adenocarcinoma

doi: 10.1002/cam4.4954

Figure Lengend Snippet: Identification of BRD9 as an essential epigenetic regulator for COAD. (A) Flowchart showing the screen procedure of epigenetic hits. (B) Summary of top 15 candidates with hazard ratios and corresponding p values. (C) The correlation heatmap indicating the underlying relationships among indicated regulators. (D) The MTT assays in SW480 cells showing that BRD9 was the most potent target relative to others. (E) CCK‐8 assays indicating the cell growth rates in SW620 or HCT‐116 cells transfected with shCtrl and shBRD9 viruses, respectively. (F) Illustration of BRD9 levels across pan‐cancer cell lines based on the CCLE dataset. Data are displayed as mean ± standard deviation. *** p < 0.001, ** p < 0.01, * p < 0.05.

Article Snippet: Then, 10 μl CCK‐8 reagent (Abcam, ab228554) was added into the cell culture 4 h before the measurement of absorbance at 450 nm.

Techniques: CCK-8 Assay, Transfection, Standard Deviation

Journal: Cancer Medicine

Article Title: BRD9 is an essential regulator of glycolysis that creates an epigenetic vulnerability in colon adenocarcinoma

doi: 10.1002/cam4.4954

Figure Lengend Snippet: BRD9 functionally promotes cell proliferation and migration of colon cancer. (A) Western‐blotting assay revealing the overexpression of BRD9 in SW620 and HCT‐8 cells relative to control. Quantification of bands with mean ± SD was conducted by ImageJ on the right. (B, C) CCK‐8 assay illustrated the proliferative ability with BRD9 overexpression in SW620 (B) and HCT‐8 (C), respectively. (D) Colony formation assay showed the enhanced ability in BRD9‐overexpressing cells (left panel). Quantification of the results were exhibited and compared on the right panel. (E) Western‐blotting assay revealing the BRD9 deficiency in BRD9‐KO cells versus normal controls in SW620 and HCT‐8 cells. Quantification of bands with mean ± SD was conducted by ImageJ on the right. (F) 3D soft‐agar colony formation assay (left panel) revealing the cell proliferation abilities in three groups (Ctrl; KO#1; KO#1 + BRD9). Quantification of assays were showed on the right statistical panel. Scale bar = 200 μm. (G) Colony formation assay (left panel) revealing the cell proliferation abilities in three HCT‐8 cell subgroups (Ctrl; KO#1; KO#1 + BRD9). Quantification of assays were showed on the right statistical panel. (H, I) Cell migration and invasion assays of SW620 cells were showed after BRD9 was knockout. Representative pictures (scale bars = 200 μm, H) and quantification (I). Data are displayed as mean ± standard deviation. *** p < 0.001, ** p < 0.01, * p < 0.05.

Article Snippet: Then, 10 μl CCK‐8 reagent (Abcam, ab228554) was added into the cell culture 4 h before the measurement of absorbance at 450 nm.

Techniques: Migration, Western Blot, Over Expression, CCK-8 Assay, Colony Assay, Soft Agar Assay, Knock-Out, Standard Deviation

Journal: Cancer Medicine

Article Title: BRD9 is an essential regulator of glycolysis that creates an epigenetic vulnerability in colon adenocarcinoma

doi: 10.1002/cam4.4954

Figure Lengend Snippet: I‐BRD9 was effective to suppress COAD growth in vitro and in vivo. (A–C) CCK‐8 assays showing the impaired cell growth rates of SW620 (A), HCT‐8 (B) and HCT‐116 (C) cells with different doses of I‐BRD9 compound. (D–F) Representative graphs of xenograft colon tumor tissues from the Vehicle and I‐BRD9 groups at Day35 were shown (D), along with quantified tumor volumes (E) and tumor weights (F).

Article Snippet: Then, 10 μl CCK‐8 reagent (Abcam, ab228554) was added into the cell culture 4 h before the measurement of absorbance at 450 nm.

Techniques: In Vitro, In Vivo, CCK-8 Assay